Efficacy of Serratus Posterior Intercostal Plane Block for Analgesia and Inflammatory Marker in Breast Surgery

Trial Title: Efficacy of Serratus Posterior Intercostal Plane Block for Analgesia and Inflammatory Marker in Breast Surgery

NCT ID: NCT06502067

Condition: Breastcancer
Perioperative Pain
Inflammation

Conditions: Official terms:
Breast Neoplasms
Inflammation

Study type: Interventional

Study phase: N/A

Overall status: Not yet recruiting

Study design:

Allocation: Randomized

Intervention model: Parallel Assignment

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Drug
Intervention name: Analgesia mangement group A,B
Description: 1gm of paracetamol, 30mg of ketorolac and 1mg Granitryl will be given twenty minutes before the end of the operation .
Arm group label: Arm B: (control group) patients will only receive general anesthesia without block.
Arm group label: will receive serratus posterior superior block using bupivacaine

Summary: To study the efficiacy of serratus posterior superior block in controlling perioperative breast cancer surgery pain and its effect on inflamatory markers.

Detailed description: Back ground The presence of pain during the initial course of treatment in women with early-stage breast cancer was associated with significantly higher levels of c-reactive protein(CRP) ,interleukin-7(IL-7)and interleukin-13(IL-13) There is evidence of effectiveness of regional block in controlling inflamatory markers Serratus posterior superior intercostal plane block (SPSIPB) is a novel Regional technique that provides analgesia in the hemithorax, shoulder, and back of the neck which proved its efficacy in controlling pain after Video assisted thoracoscopic surgery there are little epidemiological data on (SPSIPB)usage in masectomy and lumpectomy procedures and its effect on inflamatory markers Methodology: - Type of the Study: Randomized prospective comparative controlled double-blinded study - Study Setting: Ain Shams University Hospitals - Study Period: One year after approval of the protocol. - Place :Ain shams university hospitals - Study Population: Adult patients who will undergo breast cancer surgey.

Criteria for eligibility:
Criteria:
Inclusion Criteria: - Adults undergoing unilateral breast surgery under general anesthesia - Age 21 to 60 years with body mass index (BMI)=18 to 25 kg/m2 - American Society of Anesthesiologists (ASA) grade I-III. Exclusion Criteria: - Patients with Long-time use of analgesic drugs - Past history of chest surgery, - Allergy to local anesthetics, - Systemic infection, - Cognitive and language disorders precluding participation, - Patients with coagulopathy,anticoagulant users - hemodynamic unstable patients - Patients with neurology, spinal, psychiatry diseases - infection at block site - patients refused to participate in the study .

Gender: Female

Minimum age: 21 Years

Maximum age: 60 Years

Healthy volunteers: No

Start date: July 25, 2024

Completion date: July 1, 2025

Lead sponsor:
Agency: Ain Shams University
Agency class: Other

Source: Ain Shams University

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT06502067